Given the success of immune checkpoint inhibitors in KRAS mutated lung tumors with high PD-L1 expression37, it can be hypothesized that the immune rich RAS-hotspot melanomas (also characterized by high immune checkpoint iScores) may benefit from similar immunotherapies. Here, KRAS is linked to melanoma.